Cancer Advisor

Edited and Updated: June 2026  Caution to the Reader: This is a complex, evolving topic rooted in molecular biology and evolutionary dynamics. The material below has been distilled for clinical accessibility while preserving strict mechanistic accuracy. Key conceptual frameworks from the Care Oncology Clinic (COC) protocol and Thomas Seyfried’s press–pulse model are integrated throughout. Introduction Clinicians utilizing a metabolic framework often combine 4–5 repurposed prescription agents with 4–5 nutraceuticals. While this approach frequently yields 1–2 years of sustained, stable response, acquired resistance can emerge rapidly, turning stable disease into aggressive progression. When this occurs, critical clinical questions arise: How should the regimen be modified? Should mechanistically similar agents be cycled more frequently? Should dosing be intermittent rather than continuous? What ...

Quick Answer: The ROOT Protocol is a tiered, nutraceutical-based cancer-prevention framework developed by Dr. Paul Marik and Dr. Justus Hope. It begins with a three-agent foundation — green tea EGCG, curcumin, and vitamin D3 — and adds omega-3s, berberine, and sulforaphane in higher tiers. The top tier, Root 9, adds the prescription drugs celecoxib, ivermectin, and mebendazole, and is scoped by its own authors to people with hereditary cancer syndromes under specialist supervision, not general use. It is best understood as a supplement escalation ladder layered on top of the diet and lifestyle foundation described in OneDayMD's I-PREVENT Cancer Protocol . Medically reviewed and updated by the OneDayMD Editorial Team | Last updated July 12, 2026 Table of Contents 1. Why Cancer Prevention Needs a Systems-Level Rethink 2. The Metabolic Drivers Screening Doesn't Address 3. The ROOT Protocol: From 3 Agents to 9 4. Root 3 and Root 4: The Foundational Ti...

Quick Answer Dr. Thomas Seyfried , a biologist at Boston College, argues that cancer is primarily a mitochondrial metabolic disease rather than a genetic one. His core treatment framework — the Press-Pulse protocol — pairs a therapeutic ketogenic diet that restricts glucose and glutamine (the "press") with pulsed adjuncts like glutaminase-inhibiting drugs, hyperbaric oxygen, or fasting (the "pulse"). Mechanistic and preclinical evidence is strong; human evidence is a mix of promising case reports and small, mostly inconclusive trials — including a 2026 randomized pancreatic cancer trial that showed a survival trend without reaching statistical significance. Most integrative oncologists treat metabolic therapy as a physician-supervised adjunct to, not a replacement for, standard cancer care. In This Guide Who Is Thomas Seyfried? The Case Against Standard-of-Care Statistics Diet and Cancer: Why Food Isn't Neutral Cutting Off Cancer's Fu...